XNAS · Healthcare · Biotechnology
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.31 | -0.29 | +6.45% | $3.3M | ✅ Beat | +0.00% | -3.81% | — |
| 2026-03-11 | Q4 2025 | -0.27 | -0.34 | -25.93% | $9.2M | ❌ Miss | +0.00% | -13.63% | -18.76% |
| 2025-11-05 |
| Q3 2025 |
| -0.30 |
| -0.25 |
| +16.67% |
| $8.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.31 | -0.28 | +9.68% | $7.6M | ✅ Beat | +0.39% | -2.60% | +7.80% |
| 2025-03-06 | Q4 2024 | -0.27 | -0.23 | +14.81% | $2.9M | ✅ Beat | +0.44% | -0.44% | -18.22% |
| 2024-11-04 | Q3 2024 | -0.44 | -0.31 | +29.55% | $7.8M | ✅ Beat | +8.50% | +12.62% | -10.44% |
| 2024-03-07 | Q4 2023 | -0.76 | -0.57 | +25.00% | $5.8M | ✅ Beat | — | — | — |
| 2023-11-02 | Q3 2023 | -0.75 | -0.34 | +54.67% | $17.5M | ✅ Beat | -2.79% | -14.21% | +15.99% |
Showing last 8 quarters.